NCT05136755RecruitingPhase 2
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 16 Nov 2021
- Start date
- 25 Jan 2022
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- China Medical University Hospital
- Diseases
- Depression
- NCT number
- NCT05136755
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 25 Jan 2022 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Initiating or stopping formal psychotherapy within six weeks prior to enrollment
- A history of previously received electroconvulsive therapy
Other illness
- Current substance abuse or history of substance dependence in the past 6 months
- History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
- Bipolar disorder, schizophrenia or other psychotic disorder
- Severe cognitive impairment
Other
- Moderate-severe suicidal risks
- Inability to follow protocol
Who the study is looking for
- Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
- Have failed to respond to at least one antidepressant with adequate dosage and treatment duration
- Their original treatments should have been unchanged for at least 8 weeks. Some treatment-resistant patients (that is, having failed to respond to at least two different classes of antidepressants) who have started to refuse any antidepressant by themselves due to previous failure experience are also allowed, if they have already been antidepressant-free for at least 2 weeks
- 17-item Hamilton Rating Scale for Depression total score ≥ 18
- Agree to participate in the study and provide informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Psychiatry, China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.